Dermata auditor MHM resigns; prior audits flagged going concern; equity plan expanded

Dermata Therapeutics, Inc.

MHM will not stand for reappointment as auditor for FY2024; will serve until FY2023 audit or new auditor appointed.
MHM's prior audit reports for FY2021 and FY2022 contained a going-concern explanatory paragraph.
Audit committee has initiated process to select a new independent registered public accounting firm.
Shareholders approved amendment to increase shares under 2021 Omnibus Equity Incentive Plan by 513,150 to 629,069.
David Hale, Steven Mento, and Brittany Bradrick elected as Class II directors for three-year terms.

item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Dermata Therapeutics, Inc. shareholders approved Election of three Class II directors.

Proposal: director election
Outcome: passed

Exact text from the filing

The votes were cast for this matter as follows: Nominee For Against Broker Non-Votes David Hale 463,516.75 255,950 750,505 Steven J. Mento, Ph.D. 463,698.75 255,768 750,505 Brittany Bradrick 687,187.75 32,279 750,505

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Dermata Therapeutics, Inc. shareholders approved Ratification of appointment of Mayer Hoffman McCann P.C. as independent registered public accounting firm at the 2023-12-31 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-12-31

Exact text from the filing

The proposal to ratify the appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023, was approved based upon the following votes: For Against Abstain 1,432,787.75 36,347 837

View on SEC.gov

Browse all shareholder votes →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-010092

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.